Peer-influenced content. Sources you trust. No registration required. This is HCN.

BloodLonger-term Benefit of Luspatercept in Transfusion-dependent Lower-risk Myelodysplastic Syndromes with Ring Sideroblasts

In this “Letters to Blood,” the author demonstrated that luspatercept provided prolonged periods of transfusion independence (TI), significantly decreased the transfusion burden among HTB and LTB patients, and generally had an acceptable and predictable safety profile, all of which helped to maintain or enhance patient quality of life. Compared to the results from the primary analysis, these data further demonstrate the clinical benefits of luspatercept in patients with LR-MDS-RS.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form